Bronchoalveolar lavage, sputum and exhaled clinically relevant inflammatory markers: values in healthy adults. by Balbi, B et al.
REVIEW
Bronchoalveolar lavage, sputum and
exhaled clinically relevant inflammatory
markers: values in healthy adults
B. Balbi*, P. Pignatti#, M. Corradi", P. Baiardi+, L. Bianchi1, G. Brunettie, A. Radaeli**,
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ABSTRACT: Bronchoalveolar lavage (BAL), induced sputum and exhaled breath markers
(exhaled nitric oxide and exhaled breath condensate) can each provide biological insights into the
pathogenesis of respiratory disorders. Some of their biomarkers are also employed in the clinical
management of patients with various respiratory diseases. In the clinical context, however,
defining normal values and cut-off points is crucial. The aim of the present review is to investigate
to what extent the issue of defining normal values in healthy adults has been pursued for the
biomarkers with clinical value.
The current authors reviewed data from literature that specifically addressed the issue of
normal values from healthy adults for the four methodologies.
Most studies have been performed for BAL (n59), sputum (n53) and nitric oxide (n53). There
are no published studies for breath condensate, none of whose markers yet has clinical value. In
healthy adult nonsmokers the cut-off points (mean+2SD) for biomarkers with clinical value were as
follows. BAL: 16.7% lymphocytes, 2.3% neutrophils and 1.9% eosinophils; sputum: 7.76106?mL-1
total cell count and 2.2% eosinophils; nitric oxide: 20.2 ppb.
The methodologies differ concerning the quantity and characteristics of available reference
data. Studies focusing on obtaining reference values from healthy individuals are still required,
more evidently for the new, noninvasive methodologies.
KEYWORDS: Airway inflammation, bronchoalveolar lavage, exhaled breath condensate, induced
sputum, nitric oxide, normal values
B
ronchoalveolar lavage (BAL), induced
sputum, the determination of fractional
exhaled nitric oxide (FeNO) and the
measurements of many compounds in exhaled
breath condensate (EBC) represent the most
important methodologies that can give relevant
biological insight to many respiratory disorders.
BAL is performed by instilling, and recovering by
gentle suction, aliquots of sterile saline into the
sub-segmental bronchi through a fibreoptic
bronchoscope with the aim of analysing cells and
solutes from the lower respiratory tract. Induced
sputum is performed by inducing expectoration
through the inhalation of hypertonic saline, with
the aim of analysing cells and solutes considered
representative of larger airways. FeNO and EBC
share the concept of detecting one (nitric oxide;
NO) or more (in EBC) chemical compounds from
exhaled air, which can function as useful biomar-
kers providing information on the inflammatory
and oxidative pathways in the airways and
respiratory system. Despite differences in the
methodology for obtaining the biological sample
(invasive versus noninvasive), the nature of the
sample to be analysed (liquid versus breath air),
the detected biological markers useful in clinical
practice (cellular markers for BAL and induced
sputum versus exhaled molecular marker), and
even the facilities, equipment and time needed to
obtain the relevant data (table 1), these ‘‘biological
investigations’’ share a number of features. The
basic principle underlying the analysis of the data
on lung and airway biology is to provide addi-
tional information to those derived from other
more traditional diagnostic sources (e.g. imaging,
lung function).
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Each technique followed a similar development pathway, from
the first description in research centres [21–24], to procedure
standardisation, usually with the aid of ad hoc collaborative
groups or Task Forces sponsored by scientific societies [1–6],
with the aim of providing guidance for the reproducibility of
the results obtained. From an investigational point of view, all
techniques have been widely applied to more or less all disease
conditions in order to gain information on the pathogenesis of
and, ultimately, improve the ability to diagnose and treat
respiratory disorders. From a clinical point of view, each
technique has been proposed in selected clinical scenarios [7,
10–14, 16–19]. The clinical application of one of the BAL
biomarkers, i.e. cell differential count, is now widely accepted
and recommended in clinical guidelines as a diagnostic tool for
sarcoidosis and idiopathic pulmonary fibrosis [8, 9], while
other biomarkers, induced sputum cell counts and FeNO values
are considered useful additional tools in the management of
asthma [6, 7, 10–20]. In contrast, the determination of
molecular markers in EBC is still awaiting an accepted clinical
application. In this context, the collection of data from healthy
subjects to use as benchmark reference values is mandatory.
Aim of the literature review
The aim of the current review is to investigate to what extent
the issue of defining normal values in healthy adults has been
pursued for BAL, induced sputum and exhaled biomarkers.
For each methodology the current authors reviewed papers
that: 1) specifically addressed the problem of normal reference
values, i.e. disease-focused studies featuring matched control
populations were not included; 2) comprised populations of
healthy adult subjects; and 3) considered the clinically useful
inflammatory biomarkers, i.e. those used in clinical practice as
an aid in the management of respiratory patients. The authors
also included the analysis of such data for EBC, a promising
tool to identify new, noninvasive biomarkers.
Search strategy
In order to accomplish the task, a systematic literature search
was performed as follows. Pertinent studies were retrieved
using online databases for medical literature (PubMed and
HighWire Press). Reference lists from published articles or
reviews were also used, and only papers published in English
were considered. The search was further limited to studies that
enrolled .30 healthy study subjects, since below this threshold
data was considered to come from underpowered protocols.
Five reviewers (B. Balbi, P. Pignatti, M. Malerba, M. Corradi
and P. Baiardi) independently examined the titles and
abstracts of all identified papers to confirm fulfilment of
inclusion criteria. They recorded the papers’ characteristics
independently using a pre-designed data abstraction form.
BAL
In 1974, the first paper detailing BAL dealt with normal values,
as the authors selected normal subjects and patients under-
going fibreoptic bronchoscopy (FOB) for ‘‘evaluation of intra-
thoracic lesions’’ [21]. BAL is a standardised methodology. Its
reproducibility has been shown both in comparing serial BAL
data obtained by repeating the procedure up to five times with
an interval of o6 weeks in the same subjects [25] and in
TABLE 1 Clinical applications of bronchoalveolar lavage, induced sputum, fractional exhaled nifric oxide and exhaled breath
condensate in inflammatory disorders
Bronchoalveolar lavage Induced sputum Fractional exhaled nitric oxide Exhaled breath condensate
Standardisation ERS [1–3] ERS [4] ATS/ERS [5] ATS/ERS [6]
Reproducibility and
validity
Reproducibility assessed and
methodology validated in normal
subjects and disease status
(mainly ILD)
Reproducibility assessed and
methodology validated in normal
subjects and disease status (mainly
asthma, COPD)
Reproducibility assessed and
methodology validated in normal
subjects and asthma
Data available for some
mediators
Nature of sample Biological fluid containing cells
and acellular components
Biological fluid containing cells
and acellular components
Exhaled air containing NO gas Biological fluid containing
acellular components
Biomarker(s) Differential cell count,
specialised markers"
Total and differential cell count
specialised markers"
NO ppb pH, various mediators
Feasibility: facilities
and equipment
needed
Thoracic endoscopy, basic
cellular lab, outsourcing for
specialised analyses
Pulmonary function lab, ultrasonic
aerosol, basic cellular lab, outsour-
cing for specialised analyses
NO analyser EBC condenser, pH analyser,
HPLC or MS
Time for evaluation 1 working day+ 1 working day+ Online Online1, days to weeks
Main field of
application#
ILD, exposure to
toxic substances
All airway diseases, ILD,
exposure to toxic substances
Asthma and allergic diseases COPD, asthma allergy,
infections, exposure to toxic
substances
Clinical applications In the diagnostic process of sarcoidosis,
IPF and other ILDs [7–9]
As an additional method
to manage asthma [10–15]
As an additional method
to manage asthma. [15–20]
NA
ERS: European Respiratory Society; ATS: American Thoracic Society; ILD: interstitial lung diseases; COPD: chronic obstructive pulmonary disease; NO: nitric oxide; EBC:
exhaled breath condensate; HPLC: high performance liquid chromatography; MS: mass spectrometry; IPF: idiopathic pulmonary fibrosis; NA: not available. #: only
applications related to inflammatory markers in lung and airway diseases of adult patients are reported; ": specialised markers can be diagnostic in bronchoalveolar
lavage (e.g. CD1+ cells in histiocytosis X, mineralogic assays for assessing exposure) and in sputum (e.g. asbestos bodies); +: 90 mins is usually sufficient for an expert
team to obtain the results, 1 working day is intended for a report in clinical practice; 1: online evaluation in EBC is only for pH and H2O2 determination.
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comparing the results obtained in different centres [26]. This
particular study showed high (i.e. .0.8) correlation coefficients
for all cell types. It should also be considered that repeated or
serial BAL is a cause of airway inflammation in itself, not
limited to the site of first lavage and characterised by increased
proportions of inflammatory cells in BAL (mainly neutrophils).
These changes last o72 h. [27]. The fluid recovered after
infusion of the first aliquot of BAL has, in some papers, been
defined as ‘‘bronchial lavage’’, which suggests that it might
represent the airway inflammation present in larger airways
better than the later aliquots, which are supposed to better
reflect the smaller airways. This assumption, however, never
reached an accepted standardisation [3].
Over the years BAL has been used to investigate inflammatory
parameters of the lower respiratory tract, particularly in the
field of interstitial lung diseases (ILD) but also in many other
conditions, such as infection, neoplasms, exposure to toxic
substances, asthma and chronic obstructive pulmonary disease
(COPD) [2]. In addition, from a clinical point of view it has been
widely applied to many disease conditions. Apart from its use in
infections (e.g. ventilator-associated pneumonia) or in the
diagnosis of peripheral cancers, BAL has acquired an accepted
clinical role in the field of inflammatory biomarkers useful in the
diagnostic process of ILD [8, 9]. In addition, it can be diagnostic
per se in a limited number of rare disorders, e.g. increased BAL
proportions of CD1+ cells for histiocytosis X (table 1).
Results of the literature search
Focusing on studies on normal values, nine studies specifically
designed to provide data on BAL cellular normal reference
values in adult subjects, fulfilling the current literature search
criteria, have been published as observational studies (table 2)
[26, 28–35]. Eight of these were performed in North America and
only one in Europe [35]. All except one were mono-institutional.
Seven were approved by an Ethical Committee and informed
consent was obtained from participants in one further study.
Overall, 760 subjects participated in these studies and under-
went FOB and BAL in order to provide BAL reference data.
Most of the subjects were male, nonsmokers and aged ,50 yrs.
Only four studies specifically evaluated the influence of age on
BAL characteristics [26, 33–35], and most of the subjects
concerned were nonsmokers. Since the vast majority of the
studies were from North America, in particular the USA, it is not
surprising that in some cases volunteers were reimbursed for
participation. The type and number of clinical and instrumental
parameters needed to define normal subjects (i.e. the inclusion
criteria) varied greatly, from basically no specification to a
complex and costly assessment including chest radiographs,
medical history, physical examination, blood count and
spirometry or even carbon monoxide diffusing capacity
measurements. Three studies mentioned the history of allergies
as an exclusion criterion.
The number of subjects enrolled in each study varied 34–191.
The total fluid infused ranged 100–300 mL, divided into 3–10
aliquots, reflecting the high variability of accepted methodol-
ogies in performing BAL [3]. Usually BAL was performed in a
sub-segment of the middle lobe or lingula.
One study excluded the first aliquot from analysis [35]. The
majority of studies employed cyto-centrifuge to obtain cell
differential counts, i.e. the method most used nowadays
(table 3). Despite all these inconsistencies, the data are quite
consistent in defining the characteristics of normal reference
BAL at least for the differential cell count, i.e. the only BAL
biomarker with a clinical value in the differential diagnosis of
ILD. The majority of data reviewed dealt with healthy young
to middle-aged nonsmoker subjects. In these subjects the upper
cut-off points (i.e. mean+2SD) for lymphocytes, neutrophils and
eosinophils were 16.7, 2.3 and 1.9%, respectively (table 3).
Compared with nonsmokers, asymptomatic smokers have an
increased proportion of macrophages, lower percentages of
lymphocytes and usually increased percentages of neutrophils
and/or eosinophils. The limited data available on the influence
of age on BAL cell composition appear to indicate an increased
proportion of neutrophils in older subjects, a finding in line
with similar observations in induced sputum.
Acellular components of BAL
The numerous acellular components measured in BAL super-
natants only have value as investigative tools, owing largely to
the unsolved issue of the dilution factor [3]. This problem was
first approached using internal markers such as urea, but in the
latest European Respiratory Society (ERS) Guidelines it is
recommended that acellular markers be expressed in terms of
their concentration per unit of supernatant [3]. A list of normal
values is provided in the relative guidelines. The current
authors did not include this type of biomarker in the analysis
since the search criteria only focused on clinically relevant
biomarkers. This exclusion does not apply to those markers
defined as ‘‘specialised markers’’ i.e. identifying in themselves
the presence of a certain condition or exposure to some
inorganic material (e.g. asbestos bodies as exposure to asbestos;
table 1).
Problems open for discussion
The influence of age and smoking history
In spite of the great volume of data collected on BAL reference
values, most deal with young or middle-aged subjects among
whom smokers are a minority. Thus, the data available as
normal reference values for asymptomatic smokers aged
.50 yrs are rather limited.
INDUCED SPUTUM
Although spontaneous sputum analysis has been used for
many years for microbiological and cytological diagnoses, the
presence of large quantities of dead cells in spontaneous
sputum and the inability of many subjects to expectorate
spontaneously prompted the use of induced sputum as a
method for assessing airway inflammation, a methodology
first described in 1978 [22]. Thereafter, induced sputum
analysis was applied to evaluate airway inflammation in
airway diseases, in particular asthma and more recently
COPD, but also cystic fibrosis (CF) and other diseases with
pulmonary involvement such as ILD, pneumoconiosis, infec-
tions in the immunocompetent and immunocompromised host
and cancer [4, 12–14]. While the method has proven to be
reasonably safe, it can also per se induce transitory changes in
the composition of the cellular components of sputum after
24 h in healthy subjects, with an influx of neutrophils into the
airway lumen detected by induced sputum analysis [36].
International Guidelines on sputum [4] provide guidance on
B. BALBI ET AL. BAL, SPUTUM AND EXHALED BIOMARKERS
c
EUROPEAN RESPIRATORY JOURNAL VOLUME 30 NUMBER 4 771
the most appropriate methods of induction and analysis of
sputum cells and soluble mediators. The methodology has
been demonstrated to be repeatable, with a high intraclass
correlation coefficient (ICC) at least for the percentages of
eosinophils (0.94), neutrophils (0.81), macrophages (0.71) and
metachromatic cells (0.70), while total cell counts and
lymphocytes had low ICC values [37]. The method of sputum
processing can influence the results obtained, depending on
whether the sample is processed as selected portions or ‘‘in
toto’’ (presence of high numbers of squamous cells) and on
whether or not the material is solubilised with dithiothreitol
[38]. Furthermore, as for BAL, sputum should also be
processed as soon as possible or maintained at 4uC for no
more than a few hours.
Induced sputum is thus validated in normal subjects and in
disease conditions, such as asthma and COPD, and eosinophil
count is now considered as a useful additional test in the
management of asthmatic patients (table 1) [12–15, 39, 40].
Acellular components of induced sputum
Many studies have addressed the evaluation of soluble markers
in induced sputum: cytokines, chemokines, eicosanoids, mar-
kers of oxidative stress and others. Thus, potentially, many
compounds may have not only research relevance but also
clinical relevance, providing an additional parameter for
diagnosis or a reliable biomarker for the assessment of response
to therapy. Unfortunately, however, International Guidelines
state that the validity of these measurements as clinical tools
remains uncertain, and here (as in the case of acellular BAL
components) the issue of undefined dilution factor in super-
natant of induced sputum is certainly relevant [4]. As with BAL,
induced sputum may also demonstrate the presence of certain
‘‘specialised markers’’, i.e. those markers identifying a certain
condition or exposure to some inorganic material in themselves
(table 1).
Results of the literature search
Overall the current authors found only three studies primarily
focused on normal values in healthy adult subjects fulfilling
the present literature search criteria. All were mono-institu-
tional and the number of subjects involved was much lower
than for BAL. In fact, until 2000 no study was available for
sputum cell count in healthy controls, even though several
studies had previously been published with small numbers of
healthy controls as a reference group. The studies of BELDA et
al. [41] and SPANEVELLO et al. [42] were published almost
contemporarily reporting data on sputum cell count in 118 and
114 normal volunteers, respectively (table 4). Both studies
enrolled nonsmoking subjects with no history of asthma or
other respiratory symptoms, no bronchial hyperreactivity or
referred symptoms of airway infections in the months prior to
sputum induction, and with normal pulmonary function. In
the study by BELDA et al. [41], 39% of the enrolled subjects were
atopic but not exposed to the sensitising agent in the week
preceding sputum induction, whereas all the volunteers in the
study by SPANEVELLO et al. [42] were nonatopic. Sputum was
induced with different methodologies: 1) by increasing
percentages of hypertonic saline solution, 3, 4 and 5% each
for 7 min [41]; or 2) using 4.5% hypertonic saline solution
nebulised for periods of progressively increasing length (1, 2, 4,
8, and 16 min) [42]. The percentages of unsuccessful produc-
tion of sputum were 19.0 and 11.4%, respectively, in the two
studies. Sputum selected opaque and dense portions were
TABLE 2 Characteristics of focused on bronchoalveolar lavage in healthy adults
First author [Ref.] Subjects n Inclusion criteria Exclusion criteria Age yrs Smoking history Sex
WARR [28] 36 H NA (NA) 23¡1 24 NS, 12 S NA
LAVIOLETTE [29] 42 H, PFT, DL,CO Current smoking M: (19–32) 23.9
F: (20–41) 25.7
38 NS, 4 FS 22 M, 20 F
ETTENSOHN [30] 78 CXR, PFT, PE History of PD, current
smoking, Med, VI
(20–36) 26.3 NS 44 M, 34 F
Anon. [26] 191 CBC, CXR, PFT NA (19–72) 42.8¡0.9 77 NS, 50 FS, 64 S 106 M, 85 F
MERCHANT [31] 130 NA History of RD, VI NS: (20–48) 30
S: NA
111 NS, 19 S NS 70 M, 41 F, S NA
EVERSON [32] 163 H History of RS, allergies (18–35) NA 138 NS, 25 S 112 M, 49 F, 2 NA
MEYER [33] 39 H, PFT History of smoking,
allergies, RD, Dust
Group I: (20–36) 28.1¡1.3
Group II: (45–55) 50.8¡1.3
Group III: (.65) 69.3¡1.0
NS 17 M, 22 F
MEYER [34] 34 H, PFT History of smoking,
allergies, RD, Dust
Group I: (19–36) 27¡1
Group II: (64–83) 71¡1
NS 19 M, 15 F
EKBERG-JANSSON
[35]
47 NA AD, SDTh, HF, ASD, Inf, Med 60 30 S, 17 NS 47 M
Data are presented as n, (range) mean or (range) mean¡SEM. Anon.: anonymous; H: healthy; NA: not available; PFT: pulmonary function tests; DL,CO: diffusing capacity
of the lung for carbon monoxide; M: males; F: female; NS: never-smoker; FS: former smokers; CXR: chest radiograph; PE: physical examination; PD: pulmonary
diseases; Med: medication at the time of the study; VI: viral or other illness; CBC: complete blood counts; S: current-smoker; RD: respiratory disease; RS: respiratory
symptoms; dust: history of exposure to dust; AD: airways diseases; SDTh: scoliosis or deformation of thorax; HF: heart failure history; ASD: any severe disease; Inf:
infections.
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similarly processed with 0.1% dithiothreitol and cell count and
viability assessed. Both studies yielded similar results for total
cell count and for the percentages of the cells represented in
sputum samples, at least for the proportions of eosinophils
(table 5). SPANEVELLO et al. [42] observed that only sputum
macrophages and neutrophils had a normal distribution
whereas eosinophils, lymphocytes and epithelial cells did
not, suggesting the use of a nonparametric test in the
evaluation of these sputum cells. Even if both studies reported
total cell count data, neither emphasised the usefulness of
these data in the evaluation of airway inflammation. In
particular, an increase in the total cell count together with a
high percentage of neutrophils immediately suggests a
possible airway infection; on the contrary, a high percentage
of neutrophils with normal cell distribution points to different
causes of neutrophilia.
Whether the age of the subject has any influence on sputum
cell distribution is a question that was not addressed in the two
studies, since the subjects enrolled were relatively young
(mean age 36 and 38 yrs in the studies by BELDA et al. [41] and
SPANEVELLO et al. [42], respectively). In this context, the study
by THOMAS et al. [43] focused on this point and analysed 66
nonsmoking healthy adults whose age ranged 18–74 yrs. The
authors found a significant correlation between age and
sputum neutrophils in both male and female subjects, with a
notable increase in sputum neutrophils in subjects aged
.50 yrs. In fact, the effect of age on sputum cell counts has
important implications for the clinical interpretation of the
results, reinforcing the notion that control populations should
be age-matched, particularly in studies evaluating airway
inflammation (e.g. patients with COPD) [47].
The data reviewed show that for healthy adult nonsmokers the
upper cut-off points (i.e. mean+2SD) of the biomarkers with
clinical value are 7.76106?mL-1 and 2.2% for total cell count
and eosinophils, respectively (table 4).
Problems open for discussion
Amount of sputum collected
Healthy controls do not usually produce a large amount of
sputum after induction; the International Guidelines for
sputum processing [4], as well as other published studies,
have left the question open as to whether there should be a
weight threshold for the portions collected, below which the
analysis loses significance and reproducibility.
Normal upper value of sputum eosinophils
Based on the ERS International Guidelines [4] and other
studies [39, 40], a normal upper value of eosinophils of,3 % or
,2.5% has been reported. Nonetheless, more recently pub-
lished studies consider 2% as the cut-off to define sputum
eosinophilia. This discrepancy reveals a group of subjects with
eosinophils in the range 2–3% who lie in a so called ‘‘no-man’s
land’’ of sputum eosinophilia.
Evaluation of sputum neutrophilia
The normal range of sputum neutrophils still remains a matter
for evaluation. Many factors could play a decisive role in
determining neutrophil airway inflammation: aging, air pollu-
tion, endotoxin contaminant present in the environment,
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genetic factors, and also bias caused by a nonstandardised
procedure of sputum induction [48].
Influence of smoking habit on sputum cell distribution
In spite of the vast number of studies published on the effects
of smoking on airway inflammation, a study carried out on a
large cohort of smoking and nonsmoking healthy subjects is
still lacking.
Influence of sex on sputum cell distribution
BELDA et al. [41] found a significant difference in sputum
eosinophils between healthy males and females, but they consider
this a small difference. Other studies are needed to demonstrate a
possible influence of sex on sputum cell distribution.
EXHALED NITRIC OXIDE
The presence of NO in exhaled air was first described in 1991
by GUSTAFFSON et al. [23]. Since then, new discoveries have
suggested that the measurement of FeNO could be a new test
for evaluating patients with respiratory diseases, useful in
investigating airway inflammation in asthma and other airway
diseases, such as COPD or CF, and also for studying other
types of respiratory disorders such as ILD, pulmonary
hypertension, infections and occupational diseases [49].
There are, however, some important technical factors to be
taken into account. First, to measure FeNO from lower airways
it is important to maintain a consistent expiratory flow rate
[50]; faster flow rates decrease FeNO concentrations because
NO measured at high flow contains a greater proportion of
alveolar NO and less bronchial NO. A 50 mL?s-1 exhaled flow
rate has been recommended [6].
Secondly, since a large amount of NO is produced in the para-
nasal sinuses [51], it is important to ensure that the soft palate
is properly closed prior to sample collection to prevent
contamination of lower airway NO with NO from nasal
passages. Exhalation against resistance (5–20 cm H2O) is the
preferred method [6, 52].
Thirdly, differences in calibration gases may produce differing
results, although analysers from different manufacturers show
a sufficient comparability for practical purposes if proper
calibration is performed [53]. Fourthly, the influence of
ambient NO should be taken into account. Ambient NO must
be recorded at each measurement [6], although its effect may
be relevant only if it is .35 ppb, an effect that is minimal with
the inspiratory filters routinely employed.
Finally, many factors may influence FeNO measurements. They
include sex and sexual hormones, body weight and age,
circadian changes of respiratory function in health and disease,
caffeine and alcohol, meals rich in nitrate, genetic background
for some enzymes, upper respiratory tract infection, exercise,
drugs (including inhibitors of NO synthases) and of course
smoking [46, 54–73]. Moreover, FeNO levels in healthy subjects
are influenced by atopy, i.e. a personal or familial tendency to
produce immunoglobulin E antibodies in response to low
doses of allergens, usually proteins, and to develop typical
symptoms, such as asthma, rhinoconjunctivitis or eczema
dermatitis [74]. Atopy enhances FeNO levels even in the
absence of allergic symptoms and thus is a relevant confound-
ing factor. It should be considered that NO arises mainly from
epithelial cells; while there is a tendency for it to be increased
with eosinophilia, it can sometimes be increased in the absence
of eosinophilia and may be normal when eosinophilia is
present.
Considering all the above issues, the methodology has been
demonstrated to be highly reproducible. KHARITONOV et al. [75]
showed that the measurements of FeNO are reproducible
(mean¡SD 1.83¡0.75 ppb with a coefficient of variation of
9.5¡4.7%), without diurnal variation and no significant day-
to-day variation of measurements, with high feasibility [69]
and with an ICC in healthy adults .0.90.
Compared with BAL and induced sputum the evaluation of
FeNO has the advantage of being totally noninvasive, allowing
online evaluation of a biomarker. From a clinical point of view,
FeNO determination has been mainly applied in allergic airway
diseases (table 1) [19, 20]. In this context, FeNO is validated for
clinical use as an additional parameter to lung function, while
none of the other exhaled biomarkers are yet at this stage. It is
employed as an additional useful test in the monitoring of
asthmatic patients and in assessing the need for changes in
treatment regimens (table 1) [15–20].
Results of the literature search
Besides the Task Force recommendations [5], the current
authors found three studies primarily focused on normal
values in healthy adult subjects fulfilling the literature search
criteria, which were all published in 2006 (table 5) [44–46].
Overall, 2,452 subjects underwent FeNO measurements. Two
studies were performed in Europe and one in the USA. Only
one study was multicentric [46]. Ethical Committee approval
and informed consent were mandatory in all studies. For FeNO,
as for BAL and induced sputum, inclusion and exclusion
criteria differed largely, as one study had been conducted on
unselected random subjects from the general population [44].
All studies detected FeNO at a flow rate of 50 mL?s-1, while the
studies employed three different NO analysers (table 5).
The data from OLIN et al. [44], involving a large population of
randomly selected adult subjects, indicated a median FeNO
value of 16 ppb, although with a wide range (2.4–199 ppb).
The authors observed an association of FeNO values with
height and age but not with sex. However, this study also
included subjects with asthma, atopy and receiving steroid
treatment. In contrast, OLIVIERI et al. [46] specifically designed a
study to address FeNO normal values. They measured FeNO in
a population of 204 healthy nonatopic, nonsmoking subjects
aged 19–65 yrs at a flow rate of 50 mL?s-1 using the online
single breath technique and identified a mean value of
10.8¡4.7 ppb. They found a sex-related difference, as values
of FeNO were significantly lower in females at the studied
expiratory flows [46]. The effect of age was also investigated by
HAIGHT et al. [45] in a study evaluating a much smaller
population; they observed increased values in older subjects
(table 5).
On the basis of these data it can be stated that in healthy
nonsmoking adult individuals FeNO levels fall within the 4–
20 ppb range, and the value of 20.2 ppb (mean+2SD) can be
identified as a cut-off point between normal and abnormal FeNO.
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Problems open for discussion
Scarcity of normal value studies
Larger studies specifically addressing the problem of reference
values in different normal populations (considering age, sex,
smoking history, atopy, etc.) are still needed.
Outlier values
Some normal individuals have high FeNO levels: once an
underlying disease is excluded, further studies are needed to
clarify the reason(s) for these unexpected values [76].
FeNO predicted values
When a clearer picture of how important each single factor is
in determining the final FeNO values becomes available, it
might be possible to calculate a ‘‘predicted’’ normal FeNO level
for each subject; taking into account age, sex, smoking history,
etc., in a similar way as for lung physiological parameters.
EXHALED BREATH CONDENSATE
The first study on EBC was published in 1980, when authors
quantified indices of lipid peroxidation in EBC [24]. The initial
enthusiasm for this technique was later tempered by technical
and analytical difficulties, related to the low concentration of
putative biomarkers detectable in EBC, the site of EBC particle
formation and finally the need for dilution and salivary markers
for a proper interpretation of EBC studies (table 1) [6, 20].
EBC does not contain cells but mediators and chemical
compounds, which can be determined by radioimmunoassay
and enzyme immunoassay. However, most of the substances
detectable in EBC are present at trace level, thus requiring
highly sensitive assays for detection. On this basis, particular
caution should be exercised when using nonvalidated bio-
chemical techniques to make measurements close to the limit
of detectability. To improve the specificity of the measure-
ments, additional methods such as chromatography and mass
spectrometry have been employed. These sophisticated and
costly techniques increase the ability to detect and quantify the
many different EBC components, but reduce the future
prospects of a clinical application of EBC analysis, if not
carried out in specialised centres.
Recently, International Guidelines have been published with
recommendations to optimise the method and achieve better
standardisation and reproducibility of procedures [6]. EBC
collection is completely noninvasive and thus should not
encounter ethical difficulties in its widespread application to
identify reference values.
Results of the literature search
In contrast to the previous considerations, somewhat surpris-
ingly, there is no ‘‘normal reference value’’ study in the EBC
literature, i.e. no study has specifically addressed the issue of
obtaining reference data for the many molecular markers
contained in EBC from normal subjects. Thus, it is not possible
to define reference values for any EBC mediator, such as the
current authors have highlighted for BAL, induced sputum
and FeNO. At this stage, it is only possible to capitalise on
studies dealing with EBC analysis in diseased conditions,
although in these studies a limited number of healthy subjects
matching the characteristics of the diseased group are usually
used as a control group. In this context, a number of such
publications have dealt with the same mediator, therefore,
more data are available in healthy controls (table 6) [77–93].
The only exception is a recent study dealing not with a
mediator or chemical compound but with pH values in healthy
subjects [87].
Overall, given the nature of the matrix to be analysed and the
related technical difficulties, it is not surprising that no
indication for a clinical use of EBC analysis has been put
forward. The field in which EBC analysis may soon have a
recognised clinical application is in assessing exposure to
chemical compounds potentially harmful to the respiratory
system, e.g. in the screening of occupational/environmental
risk or toxic effects of a given compound in exposed
individuals [91]. This type of ‘‘occupational’’ application of
EBC analysis to detect a biomarker of exposure/effect is rather
analogous to the role of induced sputum in occupational
asthma [94], representing an example of how the development
of a new biological tool may capitalise on previous experience
with other types of sample analysis.
Problems open for discussion
Lack of studies addressing the problem of normal reference
values for mediators contained in EBC
This is the main problem, although historically it is due to the
development of the methodology, the previously mentioned
technical problems and the fact that International Guidelines
were only published in 2005. Nevertheless, it would appear that
large collaborative studies addressing this issue are needed.
Different components of EBC
EBC contains both volatile and nonvolatile nongaseous
substances. Volatile or semi-volatile substances (e.g. hydrogen
peroxide) have appreciable vapour pressure at body tempera-
ture and, therefore, can be easily exhaled like gases. Volatile
substances in gas phase dissolve in condensed water in the
EBC apparatus throughout the collection period, increasing in
proportion to their delivery to the EBC apparatus. Therefore, it
has been proposed to quantify volatile solutes in terms of the
rate at which they are dissolved in the EBC apparatus rather
than in terms of their absolute concentration. This aspect of the
assessment of EBC also needs to be performed in normal
volunteers.
Dilution factor(s)
EBC also contains nonvolatile substances, such as salt and
proteins, which are mainly added to exhaled breath in small
droplets. These are further diluted with exhaled water
vapours. Droplet formation does not proceed at a constant
rate and is not linearly related to water vapour production.
Therefore, differences in dilution of exhaled droplets by water
vapour in EBC may require the use of dilution indicators for
accurate data interpretation. Some authors have suggested
using salt concentrations (Na+, Cl-, K+) and urea as normal-
isation factors, assuming these substances to be equally
concentrated in airway lining fluid and serum of healthy and
diseased subjects. Conductivity measurement on lyophilised
EBC has also been proposed as a normalisation factor. This
part of the assessment of EBC also needs to be carried out
using normal volunteers.
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Potential confounding factors
A factor which should be taken into account in EBC analysis is
the lack of standardised measurements which may lead to
different results in separate experiments. Efforts are needed to
improve the sensitivity and the specificity of putative
measurements through a comparison with more valid tech-
niques, such as those based on mass spectrometry [95, 96].
DISCUSSION AND CONCLUSIONS
The data reviewed for the four methodologies highlights a
series of common features. The major one among them is their
ability to provide a biomarker which can have an additional
clinical value. Although the time elapsed from the first
description and the number of researchers involved for each
methodology are also important factors, somewhat surpris-
ingly studies designed to obtain reference data are more
numerous in the literature for older and more invasive
methodologies than for the newer, less invasive ones. This
fact seems to call for new and larger studies in this field.
Another possible way to increase present knowledge about the
type and characteristics of the signal gained from the new,
noninvasive methodologies may be to compare them with the
old ones in given populations of subjects. Such comparison
studies could be useful in defining the site of sampling for the
different methodologies (e.g. lower versus upper airways). In
addition they could be useful for correlating the presence of
biomarkers obtained through invasive/expensive/time-con-
suming methods with new ones hopefully obtained by new,
noninvasive/cheap/online methods. An example could be the
inclusion in the future of normal value FeNO studies of the
evaluation of induced sputum cells, to identify the presence,
type and severity of airway inflammation and to correlate this
information with that of the noninvasive biomarker. Such
comparison studies have been performed for instance between
induced sputum and EBC in chronic airway inflammatory
diseases and between BAL and EBC in ILD [90, 97, 98], as well
as between BAL and/or biopsy and induced sputum, but
clearly a deeper evaluation in this field is needed before a
reliable biomarker for clinical use can be identified [99].
In any case, before reaching the goal of clinical application for
each methodology, many obstacles have to be overcome. The
assessment of reliable normal reference values is certainly one
of the most important obstacles. In this context, the data
reviewed have revealed many common problems.
How to define a normal control subject?
This is not, as it might seem, an obvious or useless question
since there is no agreement in the literature on the inclusion
criteria for subjects enrolled as ‘‘normal control’’, even in
studies designed to obtain reference data (tables 2–6). As an
example, very few studies that specifically focused on normal
subjects managed to ascertain a status of atopy. In western
countries, atopy seems increasingly present in the general
population and its presence is relevant for all the biological
methodologies. Another example is the time that should elapse
from an acute airways infection in normal subjects to be sure
that all inflammatory parameters return to baseline values. In
this context, there is evidence that induced sputum, FeNO and
EBC may show important changes during or after a viral
infection of the larger airways or a common cold [64, 100, 101].
As these changes may last for weeks, upper respiratory tract
infection may act as a confounder in studies focused on
reference biomarkers and, consequently, the recruited subjects
should be free of such episodes for o1 month.
How to recruit normal volunteers?
To the current authors’ knowledge there are no standard
normatives in European Union countries pertaining to enrol-
ment (and possible remuneration) of normal volunteers;
although it is permitted, at least in some countries, to
‘‘reimburse’’ patients enrolled in clinical trials. Conversely,
informed consent and approval from Ethical Committees are
mandatory in Europe. This combined situation may cause
increased difficulties in recruiting normal volunteers. As
reimbursed volunteers may represent a biased population of
normal subjects, e.g. for their social status, to what extent may
the data obtained from this population be used as reference
values for the general population?
Monocentre versus multicentres
The vast majority of studies designed to obtain normal
reference data for each methodology are monocentric. Such
studies often enrol small numbers of subjects. This may be
useful since each institution should obtain its own reference
values to compare this data with that obtained from the local
TABLE 6 Selected compounds detected in exhaled breath condensate (EBC) in healthy adult subjects
Markers Methods Interpretation Values in normal subjects Refs
Hydrogen peroxide Colorimetric or fluorimetric methods Free radical production 0–0.5 mM 77–81
8-Isoprostane EIA and gas chromatography/MS Lipid peroxidation product 0–20 pg?mL-1 82–85
pH pH electrodes and indicator dyes Acid-base status 7.8–8.1 86–89
MDA Liquid chromatography-tandem
mass spectrometry
Lipid peroxidation product 0–15 nmol?L-1 90–92
TBARS Spectrofluorimeter Decomposition of lipid peroxidation
products
0–0.05 mM 78, 93
Data presented in this table are not from studies specifically addressing the issue of normal reference values for the different parameters/substances present in EBC, as
there are no such studies in the literature. Instead the data are from control subjects whose values were employed as comparison data with diseased subjects; the only
exception is [87]. MDA: malondialdehyde; TBARS: thiobarbituric acid reactive substances; EIA: enzyme immunoassay; MS: mass spectrometry.
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patient population(s). However, a mono-institutional study
often suffers from the problem of insufficient population size.
In many cases, large multicentre studies may be useful to
compare data and to pool them in larger population samples
that take into account many variables, such as sex, race, age,
smoking history, etc.
Ethical problems
Are we permitted to use data obtained from ‘‘control patient’’
populations submitted to a given methodology as reference
values in our clinical setting? To what extent may we compare
studies performed employing reimbursed volunteers with
studies performed where reimbursed volunteers are not
allowed? Should the process of reviewing manuscripts take
into account these differences?
Conclusion
In conclusion, for each methodology, and particularly for the
newer ones, there may still be the need for multicentre
collaborative studies designed to obtain control data from a
larger population of normal subjects. As a prerequisite, the
standardisation of the methodology, a well designed set of
inclusion criteria and a better definition of the characteristics of
the studied subjects should be agreed on, with the aim of
knowing exactly how and from which populations the data to
be used as reference values is obtained. In Europe, common
legislation or guidelines on this issue would be very important
to place all investigators under the same conditions when
designing their studies. Finally, the scientific community
should lobby to underscore the importance of such studies
involving normal subjects. These studies are designed to
increase current knowledge about basic processes ongoing in
the respiratory system as a means to providing, ultimately,
better care for patients.
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